Skip to main content

Table 2 Sustained Virologic Response Rates (95% Confidence Intervals) in Patients infected with HCV Genotype 1

From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

 Genotype 1 SVR, % (95% CI)Genotype 1a SVR, % (95% CI)Genotype 1b SVR, % (95% CI)
All patientsAll patientsLDV/SOFDAC + SOFSOF/VELAll patientsLDV/SOFDAC + SOFSOF/VEL
Patients who complete, N4831805211711236861437
 All durations99.2 (97.9–99.7)98.3 (95.2–99.4)96.2 (87.0–98.9)99.1 (95.3–99.8)100 (74.1–100)99.6 (97.6–99.9)100 (95.7–100)99.3 (96.1–99.9)100 (64.6–100)
 12-wk treatment99.1 (97.7–99.7)98.2 (94.7–99.4)95.8 (86.0–98.8)99.0 (94.8–99.8)100 (74.1–100)99.6 (97.5–99.9)100 (95.5–100)99.3 (96.0–99.9)100 (64.6–100)
 16-wk treatment100 (67.6–100)100 (34.2–100)NA100 (34.2–100)NA100 (51.0–100)NA100 (51.0–100)NA
 24-wk treatment100 (87.1–100)100 (79.6–100)100 (51.0–100)100 (74.1–100)NA100 (64.6–100)100 (56.6–100)100 (34.2–100)NA
SVR in the following subgroups
 No cirrhosis99.2 (97.1–99.8)97.4 (91.0–99.3)96.0 (80.5–99.3)98.0 (89.5–99.6)100 (34.2–100)100 (97.4–100)100 (92.4–100)100 (96.0–100)100 (34.2–100)
 Cirrhosis99.2 (97.0–99.8)99.0 (94.7–99.8)96.3 (81.7–99.3)100 (94.6–100)100 (70.1–100)98.9 (94.2–99.8)100 (91.0–100)98.0 (89.5–99.6)100 (56.6–100)
 Decompensated cirrhosis96.0 (80.5–99.3)92.3 (66.7–98.6)100 (70.1–100)75.0 (30.1–95.4)100 (34.2–100)100 (43.9–100)100 (34.2–100)100 (20.7–100)NA
 Treatment-naive98.2 (95.6–99.3)96.5 (90.2–98.8)93.8 (79.9–98.3)97.8 (88.7–99.6)100 (67.6–100)99.1 (95.2–99.8)100 (92.4–100)98.4 (91.3–99.7)100 (64.6–100)
 Treatment-experienced100 (98.5–100)100 (96.1–100)100 (83.9–100)100 (94.9–100)100 (43.9–100)100 (96.9–100)100 (91.0–100)100 (95.5–100)NA